๐
PM Q1 2026 Earnings Call
April 22, 2026 at 12:00 AM
๐
Company
PM
Quarter
Q1 2026
Date
April 22, 2026 at 12:00 AM
Speakers
1
Word Count
~9,292
Transcript Content
Operator
Thank you. At this time, we'll conduct a question-and-answer session As a reminder, to ask a question, you will need to press star 1-1 on your telephone and wait for a name to be announced. To withdraw your question, please press star 1-1 again. Please stand by while we compile the Q&A roster. One moment for our first question. Our first question will come from the line of Eric Sirota from Morgan Stanley. Your line is open. Eric Sirota (Other): Great. Thank you. And good morning, good afternoon, Emmanuel. Emmanuel Babeau (CFO): Good morning, Eric. Mike. Eric Sirota (Other): So starting with smoke-free or international smoke-free, your profit performance or gross margins over 70%, very impressive. You guys have spoken in the past that, well, you're still in the early innings of the optimizing the supply chain and really harvesting gross margin across international ICOS. As you look ahead, how much of a priority is that with your margins at very high levels and a lot of growth potential ahead? And then the other question was on U.S. ZIN. You know, your price gaps have certainly widened back out. They're not that far from where they were when Jacek called them out last September as being, you know, wider than you'd like. Has there been any sort of strategic change in terms of how you're thinking about what you're, you know, sort of the trade-off between pricing and market share that you're willing to, you know, that you're willing to balance in terms of US then? Emmanuel Babeau (CFO): Thank you, Eric. So, first of all, on smoke-free international margin, I mean, you're right, we continue to improve. And I would say it's a combination, first and foremost, you said it, ICO, that continue to do well. We've been increasing price in a number of markets. We're close to 3% on price increase on smoke-free. And of course, ICO is the biggest contributor to that. To be clear, that's not the top priority because we've been in many occasions explaining the fact that on ICOS and on our smoke-free portfolio globally, we are benefiting from a higher margin than on combustible, which is very nice. But also in dollar term, we are significantly above, you know, more than two times in terms of dollar per unit for revenue but also for gross profit so maximizing volume of course is a big objective but as we are building the portfolio we are building a very attractive brand with icos very differentiated but look at what we're doing with vive so they are coming more like wing brands if you want these and in international they are much smaller than icos at this stage but we are also working on the profitability of these two brands but i cause here is the big driver we do i would say the best possible job to optimize the profit per unit but we don't lose track from the fact that here the name of the game is to maximize volume because that is very powerfully contributing to our overall profitability now your second question on zine in the us i think to a large extent the premium versus competition remains the same as a few months ago let's not forget that it is a moving target because of course competition is also evolving their price and we've seen globally in the market a lot of i would say commercial aggressiveness on on on pricing Fundamentally, ZIN is the leader of the market. If you look at the brand power, ZIN stands really out versus any other brand in the market in terms of differentiation, in terms of brand strength. And this is, as a leader, a brand that will remain as the more premium brand in the market. And it's our intention that it's going to be the case. Of course, we need to permanently monitor are we, you know, with the right level of premium versus competition. And at the end of the day, while, again, we're not going to lose our compass, which is to develop a leading brand with a very nice premium and profitable positioning, we need to ensure that we have the best pricing for that and that we optimize all the parameters, including pricing, to achieve this objective. Now, of course, I'm not going to elaborate more on pricing. This is a very sensitive matter. But at the end of the day, you should just have in mind that our objective is to keep Zinn as the leading brand, a premium brand, making a big difference versus competition. And then, you know, we'll navigate the parameters to achieve that. Eric Sirota (Other): Thank you so much. I'll pass it on.
Operator
Thank you. Thank you.
Operator
One moment for our next question. our next question I'm coming from the line Bonnie Herzog from Goldman Sachs your line is open alright thank you hi Emmanuel good morning I maybe wanted to do a follow up question on Zinn in the US you know you did mention you expect performance to improve over the course of the year so maybe I'd like to better understand what gives you the confidence in this and curious to hear you know how much you're willing to to, I guess, continue to sacrifice short-term profitability to drive volume growth. And then finally, we all know you've been at a disadvantage given the FDA's failure to fast-track reviews of the NIC pouch applications. So curious if you'd consider just rolling out some of the innovation you have that you mentioned without approval. Emmanuel Babeau (CFO): Yes, sure, Benny. So happy to take this one. i'm going to repeat what i've just been saying on what is our uh objective on on zin fundamentally in in the us but i'm certainly happy to elaborate on why we expect a much more positive dynamic in the second part of the year first of all allow me to spend a few seconds on q2 so remember last year we still have a little bit of market reloading in Q2, much more moderate than in Q1. But that means that we don't have a fully underlying performance as a basis of comparison for Q2. Second, you will remember that last year in Q2, there was, again, almost no promotional activity, which means that we had an abnormally high level of revenue per can. And therefore, in Q2, we will be facing what is the growth of ZIN in the market. And every week you can track the Nielsen and that giving some views. I'm not saying it's scientifically precise, but it's giving some view on the ZIN performance. And you will have this impact on invoicing and revenue per cap. Then, in the second part of the year, that's when we get to normalization of the basis of comparison in terms of revenue per can. We should have, as well, in terms of shipment, something that is more underlying in terms of reference. There will be, of course, in Q3, this one-off operation last year of the free can that will have to be taken into account but as you know it also impacted negatively our financial performance in Q3 so that's a negative element that is not going to impact and then as we said we are expecting innovation to come in the coming months I'm not going to be able to say exactly when it's gonna it's gonna come and when it's gonna play but of course when we say we expect to be able to launch innovation in the coming months, that means that we expect innovation to positively impact our second part of the year. We'll see exactly when this is going to happen. So if you take all these elements, the capacity that we expect to have to come with innovation, to be benefiting from some of the dynamic category, the comparisons that were difficult in H1 in terms of shipment and in terms of revenue per can, all that is going to be more favorable in the second part of the year. So, I think that explains why we expect this dynamic. I'm not going to elaborate on innovation verbally and what we intend to launch. I'm sure you appreciate that this is extremely sensitive, and we're not going to share on that. But I think we're clear on our ambition to come with innovation, which is what a leader like Zinn deserves.
Operator
No, fair enough, and I appreciate that color. And then, if I may, just a question on ICOS. You know, your Q1 results came in better than your expectations, and, you know, key driver of this really was the strength behind ICOS. And, Emmanuel, you did touch on this, but I guess hoping for, you know, some more color on the drivers behind the strength and maybe what exactly came in better than your expectations. Also, I did want to just clarify if there were any timing benefits in Q1 on ICOS, I guess, just that might reverse. And then finally, as it relates to profitability on ICOS, you know, your margins continue to expand and, you know, as you mentioned, you continue to invest. So, I wanted to understand just the key drivers of profitability growth moving forward, whether it's between pricing and productivity improvements. Thank you. Emmanuel Babeau (CFO): Well, thank you, Bonnie, for giving me another opportunity to speak about ICOs because I understand why, you know, Zin is of interest and why we spend a lot of time on Zin. But clearly, we want to make sure that people understand that the biggest driver for performance globally on smoke-free international and U.S. combined is ICOs. I mean, I don't think you have any equivalent in the smoke-free space in the world to ICOs. you know, this multi-billion dollar brand, I mean, much north of 10 billion. This is a unique proposition. This is a brand that has been consistently owning around 75% of the category, which, you know, when we talk about innovation is really unusual. There is a differentiation that is very clear for the consumer. And now, of course, as we talk about the 10 billion plus brand, And this is coming with a unique brand franchise and a unique impact. So, at the end of the day, the success is explained by the fact that Icos is a great product that is meeting smokers' requirements and expectations. And that is making a clear differentiation on any other competing product. So, that is what is behind the Icos success. I mean, if I was to take one market to illustrate that, and I think it's quite remarkable in this quarter, is Italy back to a strong double-gid growth? Okay, Italy has been clearly disrupted by the flavor ban, and it took a few months, you know, to adjust. But we're back to this double-gid growth in Italy. We are reaching, you know, in some TCT, very high share in the north of 20%. And we're coming with innovation. So, you know, as I was talking about innovation for Zin a few minutes ago, a leading brand has to innovate. And I think no one is matching ICO's in terms of innovation. Terea, what we do with Delia, what we do with Livia, we are launching Bonds, and Bonds is having some very good steps in Italy very interesting to watch. I think this is the DNA of a leading, powerful brand, and that is really what is behind the success of IKOS. On the margin improvement, it's price. So, you know, we are increasing price. Not, of course, it's a very different, as I explained, it's a very different story versus combustible, but we are increasing price on IKOS and on IKOS consumability in a number of markets. We keep, of course, working on the efficiency of the supply chain, the cost of electronics of the device. We are working on our supply chain on productivity to consistently and constantly improve the cost of the consumable. So that's another driver. That is really what is behind ICO's success. I mean, I could speak for, you know, many, many minutes about the reason for ICO's success. that could have been mentioned in Taiwan, of course. I mean, it's quite impressive, you know, in a few months to reach 6% market share in Taiwan, March 8% in Taipei. And the brand was not present. So I think it just showed that even in markets where Icos is not present, the brand does exist already with a strong image. I think it's a tribute to what Icos is today.
Operator
All right. Thank you so much. Emmanuel Babeau (CFO): Thank you.
Operator
Thank you. One moment for our next question. Our next question will come from the line of Pallad Mittal from Barclays. Your line is open. Pallad Mittal (Other): Good morning. Thanks for taking my questions, three of them, and I'll take it one by one. So firstly, on nicotine pouches in the U.S., can you help us understand the excise tax environment? We have seen some proposals from a few states planning to increase excise taxes, And then earlier this month, in Canada, I think the pricing for the entire category accelerated significantly. So is there something which is changing on the tax front? And how is the industry responding to those tax increases and discussions? Emmanuel Babeau (CFO): Yeah, but I'm happy to take this one. Look, of course, as in all of us, we are hearing in a few states, not everywhere, but in a few states, discussion about putting some excise duty on nicotine pouch. Let's be cautious, you know. I will be much more comfortable to comment things when they happen because it's difficult to comment on projects, speculation. You know, we're not saying that nicotine pouch should have no taxation as a general rule. I'm not here talking only about the U.S. I think we believe there should be, in the continuum of risk, some very differentiated taxation between smoke-free products and combustible, and nicotine pouch, you know, being, of course, at a very well location in the continuum of risk should be particularly well-treated in terms of low level of fixed duty. So, for us, that should be the general behavior of regulators worldwide, and that should enable the smokers and the consumer to go toward the better product with more purchasing power. In the US, I would say this comment can be also valid because you have a regulator, the FDA that is clearly, I think, saying that these products are a much better product than a combustible cigarette that is working to accelerate a number of PMTA because they believe that consumers should have the choice between product to maybe maximize the chance of switching away from combustible cigarettes. And I believe that, you know, putting high taxes in that context is going against the intention and the vision of the FDA. So I think that would be a pity and that will not go in the right direction very clearly. Pallad Mittal (Other): Sure. And this, again, on nicotine pouches in the U.S., if I look at ZIN volume trends, based on what Nielsen data is suggesting, it might soon become a slattish volume or maybe even a declining volume number, assuming there are still delays in ZIN Ultra if I extrapolate the current trend. And clearly the PNTA timing is not in control. But what gives you the confidence that Zim Ultra, once it comes into the market, it can accelerate the growth again, any particular market from where you get this confidence? And then just also on the innovations that you are highlighting, I'm not asking you to comment on what that exactly is. But is the timing of those innovations and getting those products in the market, again, dependent on the FDA, TMDA process? Or is it something which is under your control? Emmanuel Babeau (CFO): Yeah, first on this one, on innovation, of course, you know, we follow the processes. So, again, for obvious reasons, I won't comment further on when this would come, but there is a process in the U.S. and we are following it extremely diligently. I'm stating the obvious here. On the Zyn volume evolution, so, yes, we are in the last 1,000,000, around 5%, 6% growth. I'm talking about the last weeks, you know. We'll see what is the evolution in the coming weeks, so I'm not going to speculate. But obviously, our expectation is that Zyn Ultra is going to come with a proposal. We think it's a great product, and it's going to come with a proposal that will be matching areas of strong dynamism in the nicotine pouch market today in the U.S. And therefore, we expect Zine Ultra to be able to bring some renewed momentum to the Zine brand in the coming months. That's our expectation. Pallad Mittal (Other): Sure. And then just very quickly on ICOS, so looking at the growth in Europe, around 5.5%, is it a bit lower than what you were expecting? Because historically, the growth in Europe has been high single-digit, low double-digit. And how do you plan to accelerate that 5%, 6% growth back to the high single-digit number? Emmanuel Babeau (CFO): No, the growth actually is very good in Europe because if you exclude the market that has been growing recently through the flavor ban, you are at around 8% growth. So, I would say, of course, you know, in absolute level, it would be even higher because you have a higher base, but it's very much in line with what you've seen in the past quarter. So, I would say if you put aside these two markets and Poland is a significant one plus a few disruption in Ukraine. I mean, we have ongoing disruption in Ukraine but there was a number of impact during the quarter. The rest of the market is staying extremely dynamic and we expect Poland and Hungary of course to go through this disruption and put that behind them in the coming quarters as we did in other countries in Europe. Pallad Mittal (Other): Great, thank you. Emmanuel Babeau (CFO): Thank you.
Operator
Thank you. And as a reminder that's star one one for questions, star one one. Our next question comes from the line of Andre Anden from Jefferies. Your line is open. Andre Anden (Other): Hi, good morning Emmanuel and James. Thank you for getting my questions. Firstly, in heated tobacco, could you tell us a bit more about the early trends you're detecting in Japan after the XI tax increase on the 1st of April. And then secondly, in combustibles, you mentioned in the release that in Germany you have been seeing a discernible volume decline. Is that market share driven or is the industry itself seeing a slowdown in early 2026? Emmanuel Babeau (CFO): And then finally, perhaps a bit more of a technical question, we noticed corporate expenses registered a significant year-on-year decline. could you tell us what it's attributable to and whether you expect that to persist into q2 and and beyond thank you yeah uh please take this one so on japan um look if you uh uh the comments you know we at that stage of course we're not making any comment uh it was only a fortnight ago or a bit more than the the the price increase was implemented in Japan, it's too early to say. The only thing I'm going to share is the fact that there is nothing in what we see in the first days that would, I would say, contradict what I mentioned about our confidence in the continuation of on the long term of a strong growth of the category and of the success of ICOs in Japan. But look, let's look at what's going to be the disruption in Q2, I think we explained the reversal we expect, and in a few weeks and in a couple of months, we'll be much more able to comment on the trend in Japan after this excise duty increase. In combustible in Germany, I think there was both, there is a market that is a bit weak, but the industry as well is a big week and you have some decline. So it's a combination of both, I would say, with the German consumer probably a bit under pressure. And on the corporate expense, it's largely technical. It's currency losses and transactional losses in the Q125 because that's where we are putting transactional losses. and it's by comparison effect it looks better. So that's really what is behind. But it's a Q1 event, to be clear. It doesn't mean that for the rest of the year we're not expecting things to be much more in line year-on-year on corporate expenses. Andre Anden (Other): Understood. Thank you very much.
Operator
Thank you. Thank you. And our next question will come from the line of Matt Smith from Stifel. Your line is open. Matt Smith (Other): Hi, Emmanuel. a follow-up on some of your commentary regarding ICOS by Bonds. It's launching nationally in Italy. Can you talk about the incrementality you're seeing from that offering versus trade down and the profitability today for ICOS by Bonds compared to ICOS and how you expect that to evolve and what type of scale you need for that evolution of profitability? Emmanuel Babeau (CFO): Good morning, Matt. Yeah, happy to take this one. So bonds by ICOS is, you know, as I mentioned, a very nice evolution in line with what a leader should provide to the market. I think that after now several years, we see a number of smokers who, despite the fact that ICOS is available and has been available for a while in the market, they haven't decided yet to switch to ICOS. so we came to the conclusion that there was obviously something that was not fully matching their requirement and we see the profile of this population which are very often entrenched smokers loving the kind of rough feeling coming with uh with with smoking and therefore we've been developing this bonds offering and sometime or you know in number of important number of occasion, there are people that are more looking for a mid-price positioning rather than expensive or more premium product. So we've been elaborating bonds and the consumables that come with bond, blends, exactly with this objective. And the first step in Italy and a few other markets seem to be confirmed that there is something clearly of interest for this entrenched smoker and that we could convince some of them that so far have not been switching to it not burn to switch to a better it not burn product with bonds. And in terms of profitability, as you would expect, the name of the game is that it has to be at the level of combustible as a minimum. If we can do better, we'll look at it. But certainly, it's not coming at a lower margin than our combustible business. Matt Smith (Other): Thank you for that. And a follow-up on the dynamics in Japan regarding ICOS inventories. I think you laid out the 2Q expectation pretty clearly. But as we look ahead to a second excise tax-driven price increase later in the year, was the inventory dynamic in the first quarter entirely driven by consumer pantry loading? Are there mechanisms in place to keep the wholesalers from stocking up on inventory? Just how do you think about that potential impact between the third and the fourth quarter and the second half of the year? Emmanuel Babeau (CFO): Look, we see exactly โ it's too early to talk about October. You could have some similar features that will depend, of course, on what each player is going to do in terms of price increase, and I certainly won't comment at that stage. So, you know, we'll see. Pallad Mittal (Other): It's not impossible that there will be a similar impact, but it's too early to say. Emmanuel Babeau (CFO): And allow me to come back on this question later this year when we'll have a better visibility. Matt Smith (Other): Thank you, Manuel. Emmanuel Babeau (CFO): Thank you, Matt.
Operator
Thank you. And our next question will come from the line of Faham Baig from UBS. Your line is open. Faham Baig (Other): Hi, Manuel. Well, thanks for inviting me in, hey, I'll take two questions please, both of them on SYN in the US or the nicotine pouches category. I guess the first question I have is on the category, if we look at recent scanner data, US nicotine pouch volume growth, a bit of moderated over the past three to six months. From your perspective, what are the key factors do you think that are driving this is the first one? The second one, coming back to Zyn Ultra, not really asking for timings, but how are you thinking about potential regulatory concerns around higher nicotine strengths and a broad flavor range, particularly in relation to the category attracting non-nicotine users. Emmanuel Babeau (CFO): Yes, I guess on this one, and maybe I'm going to start with that, you are probably referring to this article which, you know, was largely speculation. I think we stated very clearly that there is a very clear scientific fact that are supporting that these products are much better than smoking. You have this NYTS survey that is showing that there is no increase, there was even slight decrease in the underage usage in the U.S. according to this study. So, you know, it's difficult to see anything that has changed from the FDA perspective. And they've been giving to another product, I think it was in December, so not that long ago, which is coming with a higher nicotine content, higher than what Zin has today. And I think, you know, if they had an issue with flavor and with higher nicotine content, I doubt they would have been giving this authorization only a few months ago. So I'm not too sure what was behind this article, but for me, these are largely speculation. And I guess regarding your question on whether there is an issue with flavor and higher strength, well, they've been giving a few weeks ago approval for more flavor and higher strength. So I don't think this is something that is today a problem. On the global U.S. nicotine pouch category, look, it's very difficult to comment. Year on year, it's still growing, I think, around 25%. So, it's still extremely dynamic, incredibly dynamic. There could be some seasonality impact. Let's not be also too much impacted by the percentage because when you are having with high percentage you are having growth properly with high percentage of growth well obviously the percentage is declining but it still means that in terms of absolute number of nicotine pouch level it's still growing at the same time or even faster so let's not lose track of the real underlying growth and then And maybe as we see some new consumer to the category, there could be a question mark on at least at the beginning, and very often they are poly-user when they start using nicotine pouch, what is the average daily consumption of the new user? And maybe one of the reasons for some, you know, very slight softening of the trend in the past months may have been the fact that some of the newcomers for the time being are coming with the lower ADC but frankly beyond that I'm not sure I can I like anything then can I squeeze in a sneaky one I guess we have this high single-digit apologies we're actually running out of time we just want to to squeeze in one more analyst after you, but we'll follow up with you after. James Bushnell (Head of Investor Relations): Thank you.
Operator
Thank you. Our last question for today will come from the line of Gerald Pascarelli from Needham. Your line is over. Gerald Pascarelli (Other): Great. Thank you very much. I just wanted to ask a follow-up. How are you doing? I just wanted to ask a follow-up on the last question just on USGIN and nicotine pouch consumer dynamics. Just as the category continues to grow, it's also matured. And I guess, are we at a point now where you are seeing evidence of, I don't know, higher per capita consumers graduating from three to six milligram pouches into higher nicotine content pouches, like nine milligrams, maybe at a faster rate than we've seen in the past? And that's obviously asked in the context of Zin Ultra and whether or not by just the simple nature of having a higher nicotine content pouch on the market to compete with is enough to drive a reacceleration in volumes. Just would love your thoughts there. Emmanuel Babeau (CFO): Look, Gerald, I mean, as I explained, we see a number of higher nicotine content products and, you know, more flavor and notably fruity flavor being a more dynamic part in the market today. and that's where you have the biggest dynamism and one of the problem is that within we don't have anything above six milligrams and we have a limitation in terms of of flavors so that could be again you know i'm not going to say that i'm have any kind of strong reliable study to support that but the higher nicotine strength development could be people who are trading up a little bit from a lower nicotine content and as they evolve in their consumption but they may explore new flavors and that could be behind the new flavors fruity type development and they may also go for higher nicotine content again i'm not saying i have anything that is clearly supporting that that could be an intuition or a speculation we could make got it uh thanks very much for the color thank you thank you thank you now now turn it back over to management for clean remarks thank you for your participation in today's conference this
Operator
does include the program you may never disconnect everyone have a great day
Need more earnings data?
Explore more earnings information and financial data for PM
Transcript sourced from Financial Modeling Prep (FMP)